Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis

Introduction: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve clinical outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with forced expiratory volume in 1 s (FEV1) % pred >40%. We assessed the clinical utility of LUM/IVA in all eligible adult CF patients with FEV1 % pre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ERJ open research 2021-01, Vol.7 (1), p.203, Article 00203
Hauptverfasser:	King, Susannah J., Keating, Dominic, Williams, Elyssa, Paul, Eldho, Borg, Brigitte M., Finlayson, Felicity, Button, Brenda M., Wilson, John W., Kotsimbos, Tom
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences & Biomedicine Original Respiratory System Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction: Lumacaftor/ivacaftor (LUM/IVA) has been shown to improve clinical outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with forced expiratory volume in 1 s (FEV1) % pred >40%. We assessed the clinical utility of LUM/IVA in all eligible adult CF patients with FEV1 % pred
ISSN:	2312-0541 2312-0541
DOI:	10.1183/23120541.00203-2020